Please ensure Javascript is enabled for purposes of website accessibility

Small-Cap Biotech Stocks Are Having a Rough Year, But That Could Change in a Heartbeat

By The Daily Upside – Aug 22, 2021 at 9:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their...

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter. It's completely free and we guarantee you'll learn something new every day.

While the world's leading biotech companies — churning out Covid-19 vaccines and treatments — have hit record share prices, their small-cap rivals have been sinking. But some analysts say the latest figures suggest a bargain in the sector.

Alone In The Red

Pfizer's share price hit a record high for the first time in 20 years this month, topping $48, while vaccine partner BioNTech and rival vaccine producer Moderna have witnessed triple-digit gains in 2021. But all that success overshadows the struggles of other biotech stocks:

  • While the Nasdaq Biotech Index is up 8.7% this year, that's mostly thanks to Moderna's triple-digit growth. The SPDR S&P Biotech ETF, which gives equal weighting to companies (offering a more complete picture of small caps), has fallen 13%.
  • The healthcare sector is the only sector in the red this year on the Russell 2000 Index, which tracks small-cap stocks across several industries. Small-cap healthcare stocks are down 8.7%, while utilities are up 3.8%, energy 11.9%, real estate 14.5%, financials 19%, and consumer services an impressive 25.2%.

Playing Catch-Up: Many analysts, however, think the tide could turn soon for underperforming biotechs. That's because, historically, successes at larger biotech companies have been followed by the emergence of smaller rivals, as was the case following downturns in 2015 and 2018. "This is like being a kid in a candy store," Federated Hermes senior portfolio manager Tom Brakel told Bloomberg News of bargain biotech stock prices.

Next Up: One name that's already popped is Cassava Sciences. The company, which reported positive results for Alzheimer's treatment trials, has grown 1,500% this year after bigger rival Biogen earned FDA approval for its own treatment. Others poised for potential growth include Syros Pharmaceuticals, which will release new cancer treatment data later this year, and Karuna Therapeutic, which has had promising trials of a new schizophrenia drug.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.